Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 1-year average of -6.66, near the high end of its 1-year range (-33.21–1.39).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -6.66.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-6.66
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.15
median of 407 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
CalciMedica, Inc.
Market Cap
$4.85M
Debt to Equity Ratio
0.00
TTM Avg
-6.66
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.79M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$4.96M
Debt to Equity Ratio
1.57
TTM Avg
0.64
3Y Avg
1.33
5Y Avg
1.33
Market Cap
$4.99M
Debt to Equity Ratio
0.36
TTM Avg
0.26
3Y Avg
0.18
5Y Avg
0.25
Market Cap
$4.46M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.42M
Debt to Equity Ratio
0.90
TTM Avg
0.35
3Y Avg
0.23
5Y Avg
0.29
Market Cap
$4.41M
Debt to Equity Ratio
0.11
TTM Avg
0.30
3Y Avg
4.92
5Y Avg
3.36
Market Cap
$5.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CalciMedica, Inc. (CALC) | $4.85M | 0.00 | -6.66 | 0.00 | 0.00 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | 0.00 | 0.00 | 0.02 | 0.02 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | 1.57 | 0.64 | 1.33 | 1.33 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | 0.36 | 0.26 | 0.18 | 0.25 |
| Imunon, Inc. (IMNN)vs › | $5.21M | 1.87 | 0.21 | 0.18 | 0.20 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | 0.00 | 0.00 | 0.00 | 0.00 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | 0.90 | 0.35 | 0.23 | 0.29 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | 0.11 | 0.30 | 4.92 | 3.36 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00 | 0.00 | 0.00 | 0.03 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | 0.18 | 0.73 | 0.52 | 0.35 |
Debt/Equity
0.00
Current Ratio
5.58
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | -1.46 |
| 2025-09-30 | -33.21 |
| 2025-06-30 | 1.39 |
| 2025-03-31 | 0.79 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.01 |
| 2022-06-30 | 0.01 |
| 2022-03-31 | 0.01 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
